We are thrilled to announce our new partnership with Universimed, a renowned medical publisher, and their esteemed journal, Leading Opinions. This collaboration marks a significant step forward in our commitment to advancing oncology education.
 © OncoViews
As part of this partnership, selected OncoViews roundtables will be featured in the German and French editions of Leading Opinions. These roundtables bring together leading experts in oncology to discuss the latest research, treatment advancements, and clinical practices. By featuring these insightful discussions in Leading Opinions, we aim to reach a broader audience of healthcare professionals across Switzerland, Austria and Germany, fostering greater knowledge exchange and collaboration.
About Universimed and Leading Opinions
Universimed is a trusted name in medical publishing, known for providing healthcare professionals with the latest research, clinical guidelines, and expert opinions. Leading Opinions, one of their flagship journals, is a premier platform for sharing expert perspectives, clinical insights, and cutting-edge research in various medical fields, including oncology.
Enhancing Oncology Education and Collaboration
This partnership aligns perfectly with our mission to enhance oncology education and improve patient care through the dissemination of valuable knowledge. The inclusion of OncoViews roundtables in their journal will provide a unique opportunity for oncologists, researchers, and medical professionals to engage with contemporary discussions and emerging trends in the field.
We are excited about the potential of this collaboration to contribute to the ongoing advancement of oncology practice. Stay tuned for the upcoming editions of Leading Opinions to access these insightful OncoViews roundtables.
See the latest pieces from Leading Opinions on OncoViews:
How to handle side effects of enfortumab vedotin + pembrolizumab by Dr. Alison Birtle
Metastatic Prostate Cancer: Optimization of Systemic Treatment by Dr. Deborah Mukherji
FDA Approval
